Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Veramaris is a joint venture between Evonik and DSM-Firmenich that specializes in the production of sustainable omega-3 fatty acids from natural marine algae. The company utilizes a proprietary large-scale fermentation process to produce high-potency algal oil containing both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Their primary mission is to provide a sustainable alternative to fish oil for the aquaculture and pet food industries, reducing the reliance on wild-caught forage fish. By scaling up algal oil production, Veramaris supports the growth of sustainable salmon farming and enhances the nutritional profile of animal feed. The company operates a major manufacturing facility in Blair, Nebraska, and is headquartered in the Netherlands. Their innovation addresses critical bottlenecks in the global food supply chain while protecting marine biodiversity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Veramaris.